Clofazimine does not lead to significant QT interval prolongation: a multicentre study

Autor:	Zweijpfenning, SMH, van Groningen, H, van Ingen, J, Magis-Escurra, C, Boeree, MJ, Wagner, D, Bax, Hannelore, Andrejak, C, Wener, R, Rahman, A, Kunst, H, Lorent, N, Brouwer, MA, Hoefsloot, W, Ntm, NET
Přispěvatelé:	Internal Medicine
Rok vydání:	2018
Předmět:	Pulmonary and Respiratory Medicine medicine.medical_specialty business.industry Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] Prolongation Arrhythmias Cardiac Heart Clofazimine QT interval Long QT Syndrome 03 medical and health sciences lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] 0302 clinical medicine 030228 respiratory system Internal medicine medicine Cardiology Humans 030212 general & internal medicine Diarylquinolines Lead (electronics) business medicine.drug
Zdroj:	European Respiratory Journal, 52(5):1801386. European Respiratory Society European Respiratory Journal, 52, 5, pp. 1801386 European Respiratory Journal, 52, 1801386
ISSN:	0903-1936
DOI:	10.1183/13993003.01386-2018
Popis:	Clofazimine does not lead to significant QT interval prolongation in the treatment of nontuberculous mycobacteriahttp://ow.ly/sXC330lIbI8
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f528b4c0bddb5a44d7857b9066b30e6c https://doi.org/10.1183/13993003.01386-2018 Zobrazit plný text záznamu